Compounds > 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione
Page last updated: 2024-09-02

3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione and Sarcoma

3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione has been researched along with Sarcoma in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bartolucci, AA; Presant, CA1
Blessing, JA; Curry, SL; Hacker, N; Homesley, HD; Thigpen, JT1

Trials

1 trial(s) available for 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione and Sarcoma

ArticleYear
Phase II trial of piperazinedione in metastatic sarcoma.
    American journal of clinical oncology, 1982, Volume: 5, Issue:2

    Topics: Antibiotics, Antineoplastic; Bone Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Drug Resistance; Humans; Piperazines; Sarcoma; Soft Tissue Neoplasms; Thrombocytopenia; Time Factors

1982

Other Studies

1 other study(ies) available for 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione and Sarcoma

ArticleYear
Phase II trial of piperazinedione in patients with advanced or recurrent uterine sarcoma. A Gynecologic Oncology Group study.
    American journal of clinical oncology, 1985, Volume: 8, Issue:5

    Topics: Adult; Aged; Drug Evaluation; Female; Humans; Leukopenia; Middle Aged; Piperazines; Sarcoma; Thrombocytopenia; Uterine Neoplasms

1985